Johnson & Johnson Buys Shockwave Medical for 12 Billion

Johnson & Johnson has signed an agreement to acquire Shockwave Medical, a firm valued at $13.1 billion (12 billion euros), thus expanding the presence of the multinational led by the Spanish Joaquín Duato in the cardiovascular intervention segment and accelerating its transition to higher growth markets.

Under the terms of the transaction, which is expected to close in mid-2024 subject to approval by Shockwave shareholders as well as regulators, J &J will acquire all outstanding shares of Shockwave for $335 per share in effective, almost 5% more than the price marked at the end of yesterday’s session.

Upon completion of the transaction, which has been approved by the boards of directors of both companies, Shockwave shares will be delisted from the Nasdaq Global Select Market and the company will operate as a business unit within Johnson & Johnson MedTech.

In this sense, the multinational has specified that Michael Bodner will assume responsibility for the business once the transaction is completed, while Isaac Zacharias , who has been at Shockwave for 6 years and recently served as president and commercial director, will become global president of Shockwave. , reporting to Michael Bodner. For his part, Doug Godshall, president and CEO of Shockwave, will advise during the transition.

If you want to find more details about the acquisition of Shockwave Medical by Johnson & Johnson, download for free our companion app. Available for both Android and iOS devices, the Born2Invest mobile app keeps its readers up to date with the most important business news of the day.

Shockwave Medical Acquisition Follows Johnson & Johnson MedTech’s Purchases of Abiomed

The acquisition of Shockwave Medical follows Johnson & Johnson MedTech’s purchases of cardiac recovery specialist Abiomed and more recently Laminar.

“ The acquisition of Shockwave accelerates Johnson & Johnson MedTech’s continued efforts to increase its presence in high-growth markets ,” the company highlighted, adding that, upon closing of the transaction, Johnson & Johnson MedTech will be a leader in four cardiovascular segments. high growth.

“With our focus on innovative medicine and medical technology, Johnson & Johnson has a long history of fighting cardiovascular disease, the leading cause of death worldwide,” said Joaquín Duato, president and CEO of Johnson & Johnson, for who the acquisition of Shockwave and its technology provides a unique opportunity to accelerate the impact in cardiovascular intervention and drive greater value for patients, shareholders and healthcare systems.

__

(Featured image by  Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us